



1505 WESTLAKE AVE N, STE 750
SEATTLE WA 98109
COMMUNICATIONS@CRAB.ORG

WWW.CRAB.ORG

IMPACT REPORT 2025

CANCER RESEARCH AND BIostatISTICS

TURNING DATA INTO CURES



*OUR MISSION IS TO CONQUER CANCER AND
OTHER DISEASES USING THE TOOLS AND
EXPERTISE WE BRING TO CLINICAL TRIALS*

Table of Contents

Message from the President	3
Generating Buzz	4
NCI Projects	9
Research Services	14
Leadership and Governance	17
Friends and Supporters	19
Audit and Financial Summary	20



Message from the President

CRAB achieved several major milestones in 2025 and I am proud of what we accomplished. We activated 8 SWOG NCI-funded clinical trials and 2 additional studies within our SWOG clinical trials partnership portfolio. We also co-authored 13 manuscripts.

In early 2025, we partnered closely with colleagues at the Fred Hutchinson Cancer Center to prepare our proposal for the competitive renewal of the SWOG Cancer Research Network Statistics and Data Management Center within the National Clinical Trials Network. Led by Dr. Mike LeBlanc as Principal Investigator, with me serving as Consortium PI, the proposal was reviewed in the summer and received an excellent score; an outcome that reflects the strength of our team and our collaborative partnerships.

In the summer of 2025, CRAB supported the launch of the Vanguard study within the National Cancer Institute's Cancer Screening Research Network (CSRN), representing a major milestone. This pilot study is evaluating the feasibility of integrating multi-cancer detection approaches into clinical care, with the goal of improving early detection, particularly for cancers that are historically difficult to diagnose. CRAB provides data management support for this effort.

The ctMoniTR project, led by the Friends of Cancer Research, advanced significantly with the launch of Module 3, focusing on the use of circulating tumor DNA (ctDNA) to monitor treatment response in solid tumors excluding lung cancer. As the Independent Statistical Center, CRAB conducted meta-analyses demonstrating that reductions in ctDNA levels are associated with improved patient response to treatment. These findings have been disseminated through scientific presentations and publications.

In late 2025, the 4th Edition of the Handbook of Statistics in Clinical Oncology was published. I am grateful to my co-editors, Drs. Megan Othus and John Crowley, as well as to our colleagues around the world whose expertise and contributions made this an impactful and broadly relevant resource.

We are deeply grateful to our employees for their dedication, expertise, and commitment to our mission. Their work drives the quality and impact of our contributions across all of these initiatives. I would also like to thank our Board of Directors for their continued guidance and support during a complex and evolving funding environment. Their leadership and partnership remain essential to our ongoing success.

We look forward to building on this momentum and pursuing new opportunities in 2026.

Antje Hoering

Antje Hoering, PhD
President, Chair & CEO

Generating Buzz



SCT Presentations

Chris Cook, CRAB's Chief Technology Officer, presented at the 2025 Society for Clinical Trials conference in Vancouver, Canada, which brings together leaders from across the clinical research community. Chris's presentation, "Harnessing Artificial Intelligence (AI) in Data Management," showcased CRAB's efforts to integrate AI into its data management processes, improving efficiency while upholding rigorous data privacy standards and positioning the organization at the forefront of innovation in clinical research.



nCoup

SWOG continues its collaboration with nCoup, a provider of advanced technology solutions, to reduce duplicative data entry and minimize errors by automating the transfer of information from electronic health records to clinical research data capture systems. Currently, nine SWOG trials are using this approach, with additional studies under consideration. CRAB partners closely with nCoup to implement the EDC solution. Early results are promising, with participating sites reporting significant time savings and improved data quality. A peer-reviewed article recently published in the Journal of the Society for Clinical Data Management highlights gains in efficiency and data integrity.

Generating Buzz



ASH Clinical Training Institute

For the ninth consecutive year, CRAB's CEO served on the faculty of the American Society of Hematology Clinical Trials Training Institute. This year-long program supports early-career hematologists through individualized mentorship on research projects, as well as guidance on clinical trial design and career development.



Antje on ASA Board


CRAB's CEO completed her second year on the Board of the American Statistical Association. In addition to serving on the Founders Award Committee, she contributed to the development of the curriculum for a clinical trials certificate program, which has attracted a distinguished, world-class faculty.

Generating Buzz



New Edition of Handbook of Statistics in Clinical Oncology

In 2025, we marked an important milestone with the publication of the 4th Edition of the Handbook of Statistics in Clinical Oncology. Since the previous edition, oncology has evolved significantly, with expanding treatment options across most cancer types and the growing prominence of immunotherapies and targeted therapies as standards of care.

This updated edition features contributions from leading cancer trial statisticians and reflects current best practices in oncology trial design and methodology. We are grateful to our colleagues whose expertise and contributions have made this an important and widely relevant resource.



Generating Buzz



Publications


In 2025, CRAB biostatisticians contributed 13 peer-reviewed publications, advancing knowledge across cancer care, staging, and treatment. Studies appeared in leading journals such as Clinical Cancer Research, Journal of Clinical Oncology, and Blood. This body of work reaches clinicians and researchers worldwide and reflects CRAB's commitment to translating rigorous research into findings that improve patient outcomes.



13 peer-reviewed publications in 2025

Generating Buzz

Overall Survival (Landmarked, Adjusted for Baseline ctDNA)



*Some estimates may be unreliable due to small sample sizes or limited number of events.

FRIENDS of CANCER RESEARCH

ctMoniTR Module 3

The ctMoniTR project launched Module 3, an investigation of ctDNA for monitoring treatment response in non-lung cancer studies. Seven pharmaceutical companies donated data on breast cancer, colorectal cancer, melanoma, prostate cancer, and cervical cancer patients treated with various modalities. As the Independent Statistical Center, CRAB conducted meta-analyses which showed that decreases in ctDNA levels were associated with better patient outcomes. Despite heterogeneity across the studies, our findings highlight CRAB's leadership in advanced statistical methods and our contributions in clinical decision-making.



1,079 patients analyzed for the ctMoniTR Module 3 meta-analysis of non-NSCLC patients

NCI Projects

NCI

**Cancer Screening
Research Network**

A program of the National Cancer Institute
of the National Institutes of Health


The Vanguard Study

Testing a new way to screen for cancer



CSRN

On July 15, 2025, CRAB helped launch the NCI's CSRN Vanguard Study to assess the feasibility of multi-cancer detection tests and inform future trials. Partnering with Fred Hutch, CRAB serves as the Data Management Center, developing data systems, managing and reviewing data, and supporting study sites. Key enhancements include multilingual surveys and an expanded CSRN Portal with dashboards and tools to support research and site operations.



**1st patient registered to CSRN1
on June 18, 2025 with 1,789
enrolled by the end of 2025**

NCI

**National Clinical
Trials Network**

a National Cancer Institute program

NCTN resubmission

Every six to seven years, Fred Hutch Cancer Center and CRAB apply for renewed funding to continue their work with the SWOG Cancer Research Network, supporting ongoing clinical trials and advances in cancer care.

These grants are awarded through the National Cancer Institute's National Clinical Trials Network (NCTN) and Community Oncology Research Program (NCORP). The NCTN application was submitted in 2025 and received an excellent score. A funding decision is expected in early 2026 and will be critical to sustaining this work in the years ahead.



NCI Projects

NCTN and NCORP Study Activations

In 2025, CRAB study builders built seven studies under our NCTN and NCORP grants: S2408, MM1YA-S03, S1800E, S2417CD, S2427, S2409, and S2433. Additionally, two studies were activated through the SWOG Clinical Trials Partnership (CTP): 21CTP.LEUK01 and 21CTP.HN01. Notably, 21CTP.LEUK01— a leukemia study, is the first CTP study opened for enrollment and marks a significant milestone in the multi-year SWOG CTP initiative.

CRAB also initiated development on 12 studies in 2025 that are expected to activate in 2026: S2419, S2409, S2504, S1900N, MM10A-S04, S2424CD, S2511, S2505, S2506, S2507, 26CTP.LEUK02, and 21CTP.BREAST01. Of the studies activated, two (S1800E and S2419) required compliance for FDA submission. These studies require substantially greater complexity and effort, underscoring CRAB's expertise in clinical trial development.



SWOG Centralized Monitoring

All SWOG studies with a registrational intent require central monitoring. In 2025, CRAB's central monitoring team initiated reviews for S1800E, a Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab. The central monitoring team's goal is to complete monitoring reviews within 3 months on selected patients prior to any audits.



As of March 2026, 100% of patients that had monitoring complete were done within 3 months of initial review

NCI Projects

Recruitment & Retention

In 2025, Jamie Sundstrom, CRAB's Clinical Trial Recruitment and Retention Specialist, advanced SWOG and CSRN clinical trials by strengthening participant accrual and representation through collaboration with national committees, study teams, and patient advocates. Key initiatives included the TAKE ACTION symposia, monthly study team presentations, and creation of participant- and staff-focused resources, including SWOG's first animated patient education video and an interactive Participation Guide to make trials more accessible, representative, and responsive to patients' needs.



SWOG meetings

SWOG continued to hold hybrid Group Meetings in the Spring and Fall of 2025. The hybrid model provides opportunities for both in-person interaction as well as remote participation at these informative SWOG meetings. CRAB Data Coordinators conducted its annual Clinical Trials Training Course in the spring to 294 registered attendees.

In the fall, CRAB staff presented the eleventh annual SWOG NCI Community Oncology Research Program (NCORP) Research Base Clinical Trials Workshop to 295 registered attendees. These workshops provide training and information to oncology research professionals and site investigators on a variety of topics related to conducting research in the areas of therapeutic studies, prevention, screening and surveillance, palliative care, symptom management and survivorship and cancer care delivery. These workshops are made possible by generous funding from The Hope Foundation for Cancer Research, a public charity that supports SWOG.

NCI Projects



SWOG Lung-MAP

2025 marked significant progress for Lung-MAP 3.0, the Master Screening Protocol for Non-Small Cell Lung Cancer (NSCLC). Since its launch in Q4 2024, 11 additional next-generation sequencing (NGS) assays from commercial and academic laboratories have been added to the Approved NGS Tests list, expanding site flexibility in identifying participants and streamlining sub-study assignments. We continue to update this list to keep pace with evolving NGS technologies. In Q2 2025, S1800E was activated. As a Phase II/III non-biomarker match sub-study evaluating docetaxel and ramucirumab with or without cemiplimab, it has accrued over 84 patients to date. Activation of S1900N, a biomarker-match sub-study, is planned for Q3 2026. This Phase II study will evaluate sacituzumab govitecan and ivonescimab, either alone or in combination, against historical standard of care outcomes in previously treated patients with actionable genomic alterations.



Over 53 genetic sequencing assays approved for Lung-MAP, expanding options for patient screening and sub-study assignments



MyeloMATCH

CRAB advanced MyeloMATCH in 2025 by supporting substudies S03 (launched March 2025) and S04 and integrating its SpecTrack application with NCI's Clinical Sample Management System. MyeloMATCH, an umbrella trial that tests multiple treatments in patients with acute myeloid leukemia or myelodysplastic syndrome, includes a screening study and multiple targeted substudies. Our specimen tracking system, SpecTrack, replaces paper-based workflows with electronic data capture and integration with other systems, reducing errors, eliminating manual entry, and significantly improving the speed, consistency, and accuracy of specimen collection and tracking.



Myelomatch MM10A-S03 activated April 1, 2025 and work began on S04 in the fall of 2025


SWOG Latin America Initiative

Trials Across Borders

The SWOG Latin America Initiative (SLAI) continues to demonstrate the strength of global collaboration. Member institutions in Latin America maintained strong research momentum, helping expand enrollment by registering over 100 patients to SWOG-credited trials in 2025..




By the end of 2025, SLAI sites were actively engaged in 18 network group trials across enrollment, follow-up, and activation



The *Instituto Nacional de Cancerología* in Mexico City was both a leading SLAI site and one of SWOG's top enrollers in 2025, contributing more than 50 patients across seven network group trials.


Research Services



Friends of Cancer Research

CRAB has served as the Independent Analysis Center for the *Friends of Cancer Research* “ctDNA for Monitoring Treatment Response” ctMoniTR project since 2019. CRAB curated clinical trials datasets and conducted large-scale analyses to evaluate circulating tumor DNA (ctDNA) as a new early endpoint for clinical trials. In three research modules, we have consistently shown that early reductions in ctDNA are associated with improved patient survival across different treatment modalities and cancer types. These analyses will help advance ctDNA as a potential tool to speed drug development and provide preliminary evidence for a real-world use case.

5,781 patients analyzed for the ctMoniTR Project



Research Services


CTP studies

In 2025, the SWOG Clinical Trials Partnership (CTP) launched its first trial, 21CTP.LEUK01, marking the culmination of years of collaboration to streamline operations and expand patient access to innovative therapies. CRAB played a key role in implementing the trial's data management systems using our own customizable EDC, CRAB Nebula™. We quickly built on this momentum by activating a second study and advancing a third. Together, these milestones demonstrate a scalable model that is accelerating clinical research and broadening patient access.



SWOG CTP activated its first 2 studies in 2025: 21CTP.LEUK01 on May 15th and 21CTP.HN01 on September 15th

Patients with Valid cTNM and ALK, EGFR, or KRAS Result By Country, total n=20,580



IASLC publications

CRAB statisticians contributed to several publications for the IASLC's 9th Edition TNM Staging Project on Lung Cancer, Mesothelioma, and Thymic Malignancies, including a [study](#) investigating survival differences based on the presence of driver mutations in lung cancer, and a [study](#) of survival patterns among pleural mesothelioma patients with common molecular alterations and PD-L1 expression.

Employee Activities



Employee Activities

CRAB Employees enjoyed several social events throughout the year helping build a strong sense of community and camaraderie. We continued our long traditions of celebrating Pi Day (3/14), Seafair, and Halloween. This emphasis on connection and shared sense of purpose contributes to a culture of teamwork and positivity, where everyone feels valued, motivated, and united in advancing our mission of conquering cancer.


Board of Directors



Antje Hoering, PhD
President, Board Chair & CEO
Cancer Research And Biostatistics



John J. Crowley, PhD
Chief of Strategic Alliances
Cancer Research And Biostatistics



Melissa Alvendia, DrPH, MS
Director of Programs & Strategy
Fred Hutch Cancer Center



Jenna Bruce, JD
Partner
K&L Gates



Tim Cummins
Managing Partner & Chief Investment Officer
Sonata Capital Group



Frank X. Curci, JD
Attorney at Law & Shareholder
Buchalter Ater Wynne



Roderic Davis, MBA
Relationship Manager, Loan Officer
The Commerce Bank of WA



Gary Goodman, MD, MS
Swedish Hospital Tumor Institute
Fred Hutch Cancer Center



David Gray, PhD, MBA
Consultant
Oncology Research & Development

Board of Directors



Patrick Heagerty, PhD, MS
Biostatistics Professor
University of Washington School of
Public Health



Michael LeBlanc, PhD
Group Statistician
Fred Hutch Cancer Center



Jonathan G. Sham, MD, MBEE, FACS
Assistant Professor of Surgery
University of Washington School of
Medicine




Steve Snapinn, PhD
President
Seattle-Quilcene Biostatistics, LLC

Friends and Supporters

We would like to thank the many friends of CRAB who made generous contributions in support of our research:

- Alex Humphrey
- Amy Johnson
- Antje Hoering
- Dacia Christin
- David Gray
- Frank Curci
- Gary Goodman
- John Crowley
- Katherine H. Karp
- Mark Ward
- Michael LeBlanc
- Steven Snapinn
- Timothy Cummins

Audit & Financial Summary



2025 revenue held steady with a small decrease of 1% compared to the prior year. Revenue from all SWOG sources was 5% less than the previous year reaching \$8,755,732 in 2025. As in prior years, National Cancer Institute's National Cancer Trials Network sustained SWOG, and thus most of CRAB's federal funding for 2025; and was augmented by SWOG Clinical Trial Partner projects funded by pharma collaborators. Another NIH funded project - Cancer Screening Research Network (CSRN) - contributed an additional \$975,970 in federal and grant revenue. Clinical and Statistical Research Program contract revenue continues to diversify revenues. Unrealized investment income in our reserves and interest on our cash investments was positive in 2025.

Support and Revenue	2025	2024	2023	2022	2021
Grant	8,270,868	7,778,126	8,468,545	7,987,013	7,080,797
Contract	2,815,030	3,476,889	3,400,028	4,157,141	4,353,449
Patient/Site	0	0		0	63,890
Workshop	21,793	14,942	28,018	12,735	0
Contributions	12,312	8,304	4,309	9,647	13,039
Other	0	0		0	101
Investment	<u>222,443</u>	<u>138,806</u>	<u>224,087</u>	<u>(173,406)</u>	<u>84,733</u>
	\$11,342,446	\$11,417,066	\$12,124,987	\$11,993,130	\$11,596,009
Operating Expenses					
	2025	2024	2023	2022	2021
Research	7,626,048	8,018,128	8,774,912	8,482,772	8,072,898
Workshops	20,104	14,796	26,797	12,063	3,308
Administration	<u>3,789,042</u>	<u>3,711,103</u>	<u>3,726,140</u>	<u>3,628,826</u>	<u>3,711,171</u>
	\$11,435,194	\$11,744,026	\$12,527,849	\$12,123,661	\$11,787,377

CRAB Values



Team Player

Open Communication

Positive Attitude

Integrity

Compassion



Our mission is to help conquer cancer and other diseases using the tools and expertise we bring to clinical trials:



Clinical Trial Design



Biostatistics



Data Science



Data Management



Electronic Data Capture



Education and Training